Co-Diagnostics, Inc.(CODX)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Co-Diagnostics, Inc. (CODX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CODX at 10.3/100 on a 32-signal composite quality model, placing it at rank #2,909 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Co-Diagnostics, Inc. reports quarterly revenue of $166.1K, net income of $-6.3M, free cash flow of $-7.2M. Top institutional holders of CODX by reported 13-F value include ARMISTICE CAPITAL, JANE STREET GROUP, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CODX trades on the Nasdaq exchange and files with the SEC under CIK 1692415. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CODX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Co-Diagnostics, Inc. directly from SEC EDGAR.
AI Quality Score
10.3/100
AI Rank
#2,909
Revenue
$166.1K
Net Income
$-6.3M
Free Cash Flow
$-7.2M
CODX key financials by period
Co-Diagnostics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$622.5K
$-46.9M
—
FY 2024
10-K
$3.9M
$-37.6M
—
FY 2023
10-K
$6.8M
$-35.3M
—
FY 2022
10-K
$34.2M
$-14.2M
-78.8%
FY 2021
10-K
$97.9M
$36.7M
47.1%
FY 2020
10-K
$74.6M
$42.5M
55.9%
Institutions holding CODX
Institutional investors reporting a position in Co-Diagnostics, Inc. on SEC Form 13F.
